Engflag

Zefix

Quick links to important sections

Zefix

Zefix_EN

Method of action: Antivirals For Systemic Use

Treatment option: Hepatitis, Hepatitis B, Liver Disease, Chronic Hepatitis, Chronic Hepatitis B

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zefix

Property Description
Active ingredient Lamivudine (3TC)
Form Film-coated tablet, Oral solution
Pharmacological class Nucleoside Reverse Transcriptase Inhibitor (NRTI)
General purpose Suppression of viral multiplication
Origin Synthetic (Nucleoside analog)

Zefix: Classification and Active Ingredient

Zefix is a synthetic, prescription-only antiviral medicine characterized by its single active substance, Lamivudine, also known as 3TC. This pharmaceutical product is precisely classified as a Nucleoside Reverse Transcriptase Inhibitor (NRTI), placing it within the broader group of antiretroviral agents. This classification confirms that the medicine works by interfering directly with the reproductive cycle of the virus. Lamivudine is fundamentally a nucleoside analog, a chemically synthesized molecule structurally engineered to mimic the natural building blocks of DNA. Lamivudine's primary role is an agent that interrupts the replication of certain viruses, a function clinically recognized for decades since its introduction.

What is the Purpose and Form of Zefix?

The general therapeutic purpose of Zefix is to suppress the ability of the targeted virus to multiply within the body, thereby leading to a reduction in the overall number of circulating viral particles. This action is critical for managing the underlying condition, such as in a typical scenario where long-term viral activity must be minimized. The mechanism of Lamivudine leads to the termination of the viral DNA chain, stopping the virus from making complete copies of itself. As an oral medication, Zefix is designed for systemic action and is available in two distinct pharmaceutical preparations: a film-coated tablet and an oral solution. This dual availability, particularly the inclusion of the liquid solution, represents a key brand-level differentiation that provides necessary flexibility for consistent administration, especially important for pediatric patients or those requiring liquid formulations.

Regulatory References

  1. EMA Authorisation of Epivir (Lamivudine)
  2. Epivir (Lamivudine) EPAR Overview

What side effects are possible with Zefix?

Possible Side Effects and Safety Information

The safety profile for Zefix (Cefixime) is based on official government regulatory documents, outlining adverse reactions by frequency and potential risks to specific organ systems and patient populations.

Common and Less Common Adverse Reactions

The most common adverse reactions reported in clinical trials are predominantly gastrointestinal and include diarrhea (occurring in approximately 16% of patients), nausea (7%), loose stools (6%), and abdominal pain (3%).

Less common adverse reactions reported in post-marketing surveillance or with an incidence of less than 2% include:

  • Hepatic Disorders: Hepatitis, jaundice.
  • Renal Disorders: Acute renal failure.
  • Nervous System: Seizures.
  • Hematological Disorders: Thrombocytopenia, leukopenia, neutropenia.

Serious Adverse Reactions

Specific serious adverse events documented in regulatory sources include:

  • Hypersensitivity: Severe allergic reactions, including anaphylaxis (anaphylactic shock), and fatalities have been reported.
  • Severe Skin Reactions: Serious cutaneous reactions such as Stevens-Johnson syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Erythema multiforme.
  • Gastrointestinal: Clostridium difficile-Associated Diarrhea (CDAD), which may range from mild diarrhea to fatal colitis.

Safety Restrictions and Precautions

Contraindications include known allergy to Cefixime or to any other cephalosporin antibiotics.

Population-Specific Cautions:

  • Renal Impairment: Dose adjustment is mandatory for patients with impaired kidney function to avoid increased blood levels and potential side effects, such as seizures.
  • Coagulation Risk: Caution is advised in patients with poor nutritional status, kidney or liver dysfunction, or those on prolonged courses, as Zefix may be associated with prolonged prothrombin time and potential bleeding when used with anticoagulants like warfarin.
  • Phenylketonuria (PKU): Chewable formulations contain phenylalanine.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents for Zefix (Lamivudine) define the overdose profile based on the drug's established acute toxicity and mandated emergency response procedures.

Property Official Regulatory Finding
Documented Presentations No specific signs or symptoms of acute overdose have been identified in humans other than those reported as known adverse reactions (e.g., headache, nausea, fatigue). Acute, very high-dose exposure in animal studies did not result in organ toxicity.
Immediate Action Any suspected overdose requires the patient to seek urgent medical attention. Management relies on symptomatic and supportive treatment.
Antidote Information No specific antidote is known for Lamivudine overdose. The drug is negligibly removed by standard hemodialysis procedures.

Required Emergency Response

  • Call Emergency Services: Immediately call emergency services or the poison control helpline if the person has collapsed, had a seizure, has trouble breathing, or cannot be awakened.
  • Clinical Monitoring: Following an overdose event, the patient must be monitored closely, and management will focus on continuous supportive treatment and observation of vital signs.

The regulatory findings define the Zefix overdose profile by establishing that unique acute toxicity is not documented, thus emphasizing that seeking urgent medical care for general supportive measures and monitoring is the paramount requirement, regardless of the severity of initial manifestations.

Therapeutic Uses of Zefix

What Zefix Treats: Main Uses and Benefits

Zefix (Lamivudine) is commonly used in situations involving the long-term management of chronic viral infections, addressing the measurable activity of the viruses. Its uses are relevant for conditions presenting with systemic or localized discomfort related to chronic Hepatitis B virus (HBV) and, when part of a multi-drug regimen, Human Immunodeficiency Virus type 1 (HIV-1). The medicine is applied when evidence suggests ongoing viral activity and corresponding physiological strain.

Therapeutic Benefit

The medication is relevant in clinical settings marked by systemic imbalance and conditions involving inflammatory or irritative processes. Zefix is applied across therapeutic domains to help manage symptoms that interfere with daily functioning by supporting virologic control, which generally contributes to easing the overall symptom load. This action helps to support the patient during difficult episodes and contributes to maintaining functional stability over time. The treatment is used within conditions characterized by periods of heightened symptoms to support the patient's long-term health strategy.

“The treatment is used within conditions characterized by periods of heightened symptoms to support the patient's long-term health strategy.”

Quick Fact: Support for Chronic Viral Conditions
Zefix is generally used in scenarios where symptoms related to systemic imbalance and symptoms linked to organ-specific functional stress need continuous management, helping patients cope more steadily with symptom fluctuations.

Eligibility and Restrictions for Use

Eligibility and Restrictions for Zefix (Lamivudine)

The official eligibility profile for Zefix is governed by regulatory status (FDA/EMA) concerning patient population, age, and specific health conditions.

Classification Eligibility Status Basis in Regulatory Documents
Contraindication Must not use Documented hypersensitivity reaction to lamivudine or any component of the formulation.
Age Thresholds Approved Use Adults are the standard population. Pediatric use is established for HIV-1 in children aged 3 months and older and for HBV in children aged 2 to 17 years (U.S. label).
Use Not Established Not recommended Safety and efficacy have not been established in infants younger than 3 months for HIV-1 or in children younger than 2 years for HBV.
Conditional Use Restricted Eligibility requires close monitoring in geriatric patients (age ge 65) and is conditional on renal function for all patients.

Condition-Specific Eligibility Rules:

  • Renal Impairment: Patients with a Creatinine Clearance (CrCl) of less than 50 mL/min are eligible only if the dose is formally adjusted according to their reduced kidney function.
  • Co-infection Status: For patients with both HIV-1 and HBV, the dose must be the higher amount intended for HIV-1 combination therapy, as using the lower HBV-specific dose is officially discouraged due to the high risk of HIV resistance.
  • Pregnancy/Lactation: Use during pregnancy is conditional on the potential benefit outweighing the potential risk. Breastfeeding is not recommended for mothers who are HIV-1 positive.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Zefix (Lamivudine) primarily interacts with other medications through effects on its renal elimination from the body. It does not typically interact with medicines that are metabolized by the liver’s CYP450 enzyme system, as only a small portion of the drug is eliminated this way.

Key Interacting Medicines and Classes

Interacting Product/Class Interaction Type and Effect Regulatory Classification
Trimethoprim/Sulfamethoxazole (Co-trimoxazole) Pharmacokinetic: The Trimethoprim component, an inhibitor of renal transporters ( OCT2, MATE1), increases Lamivudine’s concentration in the blood by approximately 40%. Caution, Monitoring Required
Other Lamivudine-Containing Products Use is strictly avoided as it can result in an overdose and increased risk of side effects. Contraindicated/Avoid
Sorbitol-Containing Oral Liquids Pharmacokinetic: Sorbitol reduces the absorption of Lamivudine from the gut in a dose-dependent manner, potentially lowering the medicine’s effectiveness. Avoid Chronic Co-administration

For most patients with normal kidney function, the interaction with standard doses of Trimethoprim/Sulfamethoxazole does not require a change in Zefix dosage, but clinical monitoring is advised. Patients with existing kidney impairment should be closely monitored if co-administering any medications that affect renal clearance, as the risk of increased Zefix concentrations is higher in this population. It is also advised to avoid other nucleoside analogues like Zalcitabine or Stavudine due to potential therapeutic antagonism or additive toxicity.

Mechanism of Action

Molecular Activation and Viral Enzyme Targeting

Zefix's mechanism begins with its conversion to the active form, Lamivudine Triphosphate (3TC-TP), inside the host cell, an essential step mediated by host kinases. This active metabolite targets the viral enzymes Reverse Transcriptase and HBV Polymerase, acting as a structural mimic of the natural nucleoside substrate. This specific interaction immediately initiates the cascading effect that inhibits viral multiplication.

DNA Chain Termination

The core mechanism involves competitive inhibition where 3TC-TP is preferentially incorporated into the growing viral DNA chain by the viral enzyme. Because the incorporated molecule lacks the necessary 3'-hydroxyl ( 3'-OH) group, the viral enzyme cannot add the next building block, causing an instant and terminal arrest of DNA synthesis. This results in the drug's primary physiological effect: a virustatic reduction in the overall rate of viral multiplication throughout the body.

Constraints on Mechanistic Efficacy

The sustained functional activity of the mechanism is constrained by two biological factors: the efficiency of host cell kinases to activate the prodrug, and the possibility of viral resistance through mutations, such as M184V/I, in the target enzymes. These mutations reduce the enzyme's affinity for 3TC-TP, which can compromise the drug's ability to sustain the inhibition of viral DNA synthesis.

Dosage and Administration Information

Instruction Map: How to use Zefix — Official Administration Guidelines

Zefix (Lamivudine) is strictly an oral medicine available as a film-coated tablet and an oral solution, defining the official route of administration.

Feature Official Instruction
Dosing Schedule Varies by condition. The standard adult dose for chronic Hepatitis B is 100 mg once daily. For HIV-1, the dose is 300 mg total daily, administered as 150 mg twice daily or 300 mg once daily.
Timing & Preparation The medicine may be taken with or without food. Tablets should be swallowed whole, but if necessary, they can be crushed and mixed with a small amount of liquid or semi-solid food for immediate consumption.
Renal Adjustment Dose reduction is mandatory for adult patients with impaired kidney function (Creatinine Clearance <50 mL/min). The oral solution is frequently used to achieve the required precise lower doses.
Special Restrictions The product must not be used concomitantly with other medicines containing Lamivudine or Emtricitabine. When dose adjustment is required, the individual component should be used instead of any fixed-dose combination product.

Connection to the overall use protocol

The official use protocol establishes a standardized oral administration that is flexible regarding meal timing but places a high procedural requirement on dosing. The regimen is strictly determined by the viral condition (100 mg vs. 300 mg), and the mandatory dose adjustment based on renal function ensures use is adapted to the patient’s physiological status.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Zefix (Lamivudine)

Evidence Base for Chronic Hepatitis B (HBV) Infection

The research base that was studied for Zefix (Lamivudine) includes Randomized Controlled Trials (RCTs)—some of which were placebo-controlled—along with long-term open-label extension studies, systematic reviews, and meta-analyses. Research examined various outcomes, including whether the medicine was associated with a decrease in the amount of HBV DNA (the virus’s genetic material) measured in the blood. Studies also monitored changes in certain liver enzymes, such as ALT, which are outcomes linked to inflammatory or irritative states.

Findings from these studies data show patterns related to viral suppression and changes measured during the study period in liver enzyme levels in the observed populations. For some patients, research also described findings related to outcomes linked to inflammatory or irritative states, as assessed in tissue samples. However, a key area of uncertainty remains related to the long-term use of Zefix as a single therapy, specifically the emergence of viral resistance, meaning the initial patterns observed in the studies may diminish over time.

Evidence Base for Human Immunodeficiency Virus Type 1 (HIV-1) Infection

For Human Immunodeficiency Virus type 1 (HIV-1) infection, Zefix was evaluated in numerous large-scale clinical trials, specifically as a component of a multi-drug Antiretroviral Therapy (ART) regimen. The main research examined its role within these combinations by focusing on whether the full regimen was associated with a sustained reduction of the HIV-1 RNA viral load to undetectable levels. Studies also monitored the immune system's response by tracking changes in CD4+ cell counts.

These combination studies often compared Zefix-containing regimens against other standard regimens, and data show patterns related to viral suppression and changes in CD4+ cell counts over the course of the trials. Because Zefix is studied for use in combination therapy for HIV-1, the evidence is limited in isolating the effects of the single drug alone. Furthermore, the existing research consistently shows that Zefix was associated with the emergence of viral resistance if it is used without other antiretroviral medicines.

Key Studies & References

  1. What to Start: Initial Combination Antiretroviral Regimens - NIH (Adult and Adolescent Antiretroviral Guidelines)

Frequently Asked Questions (FAQ)

Common questions about Zefix (FAQ)

Q: What is Zefix used for?

A: Zefix (active ingredient: Zefoxetin) is a prescription medication indicated for the management of certain symptoms associated with Condition X, as defined by its official regulatory label. It is typically prescribed after a comprehensive evaluation by a healthcare provider.

Q: How should I take Zefix?

A: Specific instructions on how to use Zefix, including the dosage, timing, and any preparation steps, should only come from your prescribing healthcare professional or pharmacist. The drug's official label provides detailed information on administration, but personalized guidance is necessary to ensure safety and effectiveness.

Q: What should I do if I miss a dose of Zefix?

A: If you miss a dose of Zefix, consult the Patient Information Leaflet that came with your medication for guidance. In general, your healthcare provider will offer specific instructions on how to proceed. It is typically advised not to take two doses at once to make up for a missed dose.

Q: Can Zefix interact with other medications?

A: Yes, Zefix may interact with various other medications, including prescription drugs, over-the-counter products, and herbal supplements. It is essential to provide your doctor or pharmacist with a complete list of all products you use to allow them to check for potential interactions and adjust your treatment plan if necessary.

Q: Are there common side effects associated with Zefix?

A: As with many medications, Zefix is associated with potential side effects. The most frequently reported effects, as listed in the product's official safety information, often involve the digestive system or temporary changes in mood/sleep patterns. If you experience any severe or concerning symptoms, you should contact a healthcare professional immediately.

How should Zefix be stored and disposed of?

Storage and Disposal Requirements

Official labeling mandates specific storage and disposal procedures for Zefix (lamivudine) to ensure stability and safety.

Requirement 100 mg Film-Coated Tablets 5 mg/mL Oral Solution
Max Storage Temperature Not exceeding 30 C Below 25 C
Protection Store in original blisters, away from moisture, heat, or sunlight
Post-Opening Stability Not applicable Discard one month after first opening
Child Safety Keep this medicine out of the sight and reach of children

All unused or expired Zefix must be disposed of in accordance with local regulations; do not throw away in wastewater or household rubbish. Unused oral solution should be returned to a pharmacist for safe disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagJapan

Equivalent of Zefix found in:

A-Z Index: